Latest Medical Technology News

Clever Culture Systems has validated and launched an AI-driven analysis module for smaller contact plates, significantly expanding its pharmaceutical market reach and recurring revenue potential.

ParagonCare Limited reported a solid FY25 with $3.6 billion in revenue and $95.2 million underlying EBITDA, marking progress in its integration and growth strategy across Asia Pacific. The company is poised for further profitability improvements and expansion in FY26.

Paragon Care Limited reported solid FY25 results with revenue climbing to $3.61 billion and underlying EBITDA rising 3%, driven by successful integration and expansion into new healthcare segments.

EBOS Group Limited reported solid FY25 results with 12% revenue growth and strategic acquisitions, setting sights on continued expansion and operational efficiency in FY26.

EBOS Group Limited reported a steady FY25 with 12% revenue growth and EBITDA in line with guidance, driven by strong healthcare and animal care segments. The company signals confidence with maintained dividends and a positive FY26 outlook.

Integral Diagnostics (IDX) reported a robust FY25 with 33.7% revenue growth and operating EBITDA margin expansion, driven by the Capitol merger and organic growth. The company exceeded synergy expectations and outlined a confident outlook amid favourable industry tailwinds.

Artrya Limited has secured FDA 510(k) clearance for its Salix Coronary Plaque module, enabling near real-time detection of high-risk coronary artery plaque and opening a lucrative U.S. market opportunity with a $950 reimbursement per scan.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the fiscal year ending June 30, 2025, signaling steady returns for shareholders.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.

Altitude Minerals has identified significant concentrations of zircon and titanium minerals in new samples from its EL7071 tenement in South Australia's Eromanga Basin, setting the stage for a planned drilling campaign in September 2025.